Back to companies

Intellia Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Intellia Therapeutics Inc (Intellia Therapeutics) is a clinical-stage gene editing company focused on developing medicines with CRISPR-based therapies. The company's products include Lonvoguran Ziclumeran for the treatment of hereditary angioedema and Nexiguran Ziclumeran for the treatment of transthyretin amyloidosis. Intellia Therapeutics is also developing pipeline for the indication of hemophilia B. It works in partnership with Regeneron, ReCode Therapeutics, SparingVision, ONK Therapeutics, Kyverna, and AvenCell to develop drugs. Intellia is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Intellia Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Intellia Therapeutics Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address 40 Erie St Ste 130, Cambridge, Massachusetts, 02139-4254
Website www.intelliatx.com
Telephone 1 857 2856200
No of Employees 377
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange NTLA (NASD)
Revenue (2024) $67.7M 16.9% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 20.5% (2024 vs 2023)
Market Cap* $1.5B
Net Profit Margin (2024) XYZ 32.0% (2024 vs 2023)
* As of and is in US$
View Intellia Therapeutics Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Intellia Therapeutics Inc premium industry data and analytics

40+

Pipeline Drugs

Identify which of Intellia Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Intellia Therapeutics Inc’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate Intellia Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Clinical Trials

Determine Intellia Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Lonvoguran Ziclumera: Hereditary Angioedema
Nexiguran Ziclumeran: Transthyretin (ATTR) Amyloidosis
Hemophilia B:
Understand Intellia Therapeutics Inc portfolio and identify potential areas for collaboration Understand Intellia Therapeutics Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Intellia Therapeutics Inc Pfizer Inc Bayer AG Novo Nordisk AS Takeda Pharmaceutical Co Ltd
Headquarters United States of America United States of America Germany Denmark Japan
City Cambridge New York City Leverkusen Bagsvaerd Chuo-Ku
State/Province Massachusetts New York Nordrhein-Westfalen - Tokyo
No. of Employees 377 75,000 87,757 64,974 47,029
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Frank Verwiel, M.D. Chairman Executive Board 2017 63
John M. Leonard, M.D Director; Chief Executive Officer; President Executive Board 2014 68
Edward J. Dulac Chief Financial Officer; Executive Vice President Senior Management 2024 51
David Lebwohl, M.D. Chief Medical Officer; Executive Vice President Senior Management 2020 71
Birgit Schultes, Ph.D. Executive Vice President; Chief Scientific Officer Senior Management 2025 63
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Intellia Therapeutics Inc key executives to enhance your sales strategy Gain insight into Intellia Therapeutics Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?